scholarly journals Antihyperlipidaemic Efficacy of Trachyspermum ammi in Albino Rabbits

2009 ◽  
Vol 78 (2) ◽  
pp. 229-236 ◽  
Author(s):  
Ijaz Javed ◽  
None Zia-Ur-Rahman ◽  
Muhammad Z. Khan ◽  
Faqir Muhammad ◽  
Bilal Aslam ◽  
...  
Keyword(s):  
Body Weight ◽  
Ldl Cholesterol ◽  
Hydrolytic Enzymes ◽  
Hdl Cholesterol ◽  
Dosage Level ◽  
Cholesterol Content ◽  
Lipid Lowering ◽  
Trachyspermum Ammi ◽  
Lowering Drug ◽  
Coa Reductase

The objective of the present study was to investigate the antihyperlipidaemic efficacy of Trachyspermum ammi (L) Sprague, seed (Ajowan) powder in albino rabbits. Hyperlipidaemia was induced with butter ad libitum and oral intubation of cholesterol 400 mg/kg body weight. Simvastatin, (Tablet survive®) was used as a synthetic cholesterol lowering drug. The results suggest that 2 g/kg T. ammi seed powder produced hypolipidaemic activity, rendering 49%, 53%, 71% and 63% reduction in total lipids, triglycerides, total cholesterol and LDL-cholesterol, respectively. However, at this dosage level 62% increase in the value of HDL-cholesterol was induced by T. ammi seed powder. Nonetheless, 0.5 g/kg and 1 g/kg T. ammi seed powder did not show antihyperlipidaemic activity. T. ammi seed powder at the rate of 2 g/kg and simvastatin (0.6 mg/kg body weight) were equally effective in treating hyperlipidaemia in albino rabbits. Moreover, this dosage level also significantly reduced the cholesterol content of liver tissue. It can be anticipated that the lipid lowering mechanism may involve enhanced removal or catabolism of lipoproteins, inhibition of HMG COA reductase, and/or inhibition of lysosomal lipid hydrolytic enzymes secreted by the liver.

Effects of diacerein intake on cardiometabolic profiles in type 2 diabetics: a systematic review and meta-analysis of clinical trials.

2020 ◽  
Vol 27 ◽  
Author(s):  
Peyman Nowrouzi-Sohrabi ◽  
Reza Tabrizi ◽  
Mohammad Jalali ◽  
Navid Jamali ◽  
Shahla Rezaei ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trials ◽  
Body Weight ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Meta Analysis ◽  
Hdl Cholesterol ◽  
Cochrane Central Register ◽  
Statistical Heterogeneity

Introduction: A systematic review and meta-analysis of clinical trials was undertaken to evaluate the effect of diacerein intake on cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM). Methods: Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square (I2 ) statistic. Data were pooled using random-effect models and weighted mean difference (WMD). Results: From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c) (WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2 = 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P= 0.026; I2 = 9.5%) were identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD - 9.00; 95%CI -22.57 to 4.57; P= 0.194; I2 = 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI 0.95 to 1.73; P= 0.569; I2 = 2.2%), body weight (WMD -0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to 23.03; P= 0.963; I2 = 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2 = 0.0%), HDL-cholesterol (WMD -0.96; 95%CI -2.85 to 0.93; P= 0.321; I2 = 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2 = 37.8%). Conclusion: Diacerein intake may reduce HbA1c and BMI; however, no evidence of effect was observed for FBS, HOMA-IR, body weight, triglycerides, total-cholesterol, HDL-cholesterol or LDL-cholesterol.

scholarly journals Effect of a 1-year controlled lifestyle intervention on body weight and other risk markers (the Healthy Lifestyle Community Programme, cohort 2)

Obesity Facts ◽  
2021 ◽  
Author(s):  
Christian Koeder ◽  
Ragna-Marie Kranz ◽  
Corinna Anand ◽  
Sarah Husain ◽  
Dima Alzughayyar ◽  
...  
Keyword(s):  
Body Weight ◽  
Chronic Disease ◽  
Waist Circumference ◽  
Lifestyle Intervention ◽  
Ldl Cholesterol ◽  
Community Support ◽  
Hdl Cholesterol ◽  
Group Differences ◽  
Risk Markers ◽  
Northwest Germany

Introduction: The prevalence of obesity is high and increasing worldwide. Obesity is generally associated with an increased risk of chronic disease and mortality. The objective of the study was to test the effect of a lifestyle intervention on body weight and other chronic disease risk markers. Methods: A non-randomized controlled trial was conducted, including mostly middle-aged and elderly participants recruited from the general population in rural northwest Germany (intervention: n = 114; control: n = 87). The intervention consisted of a 1-year lifestyle programme focusing on four key areas: a largely plant-based diet (strongest emphasis), physical activity, stress management, and community support. Parameters were assessed at baseline, 10 weeks, 6 months, and 1 year. The control group received no intervention. Results: Compared to control, in the intervention group significantly lower 1-year trajectories were observed for body weight, body mass index (BMI), waist circumference, total cholesterol, calculated LDL cholesterol, non-HDL cholesterol, remnant cholesterol (REM-C), glucose, HbA1c, and resting heart rate (RHR). However, between-group differences at 1 year were small for glucose, HbA1c, and cholesterol (apart from REM-C). No significant between-group differences were found for 1-year trajectories of measured LDL cholesterol, HDL cholesterol, triglycerides, insulin, blood pressure, and pulse pressure. Conclusion: The intervention successfully reduced body weight, BMI, waist circumference, REM-C, and RHR. However, at 1 year, effectiveness of the intervention regarding other risk markers was either very modest or could not be shown.

Complex lipid-lowering treatment options in patients with a history of acute coronary syndrome

2011 ◽  
Vol 152 (8) ◽  
pp. 296-302 ◽  
Author(s):  
Győző Dani ◽  
László Márk ◽  
András Katona
Keyword(s):  
Acute Coronary Syndrome ◽  
Serum Lipid ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Lipid Lowering ◽  
Coronary Syndrome ◽  
Target Values ◽  
History Of ◽  
Lipid Parameters

Authors aimed to assess how target values in serum lipid concentrations (LDL- and HDL-cholesterol, triglyceride) can be achieved in patients with a history of acute coronary syndrome during follow up in an outpatient cardiology clinic. Methods: 201 patients with a history of acute coronary syndrome were included and were followed up between January 1 and May 31, 2007.Authors analyzed serum lipid parameters of the patients and the lipid-lowering medications at the time of the first meeting and during follow up lasting two years. Results: During the enrollment visit only 26.4% of the patients had serum LDL cholesterol at target level, whereas high triglycerides and low HDL cholesterol levels were observed in 40.3% and 33.3% of the patients, respectively. Only 22 patients (10.9%) achieved the target levels in all three lipid parameters. Of the 201 patients, 179 patients participated in the follow up, and data obtained from these patients were analyzed. There was a positive trend toward better lipid parameters; 42.5% of the patients reached the desired LDL-cholesterol target value and 17.3% of the patients had HDL-cholesterol and triglycerides target values. Conclusions: These findings are consistent with those published in the literature. Beside the currently used therapeutic options for achieving optimal LDL-cholesterol, efforts should be made to reduce the so-called “residual cardiovascular risk” with the use of a widespread application of combination therapy. Orv. Hetil., 2011, 152, 296–302.

scholarly journals Isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids improves plasma lipids in hypercholesterolaemia: a double-blind, placebo-controlled trial of a yoghurt formulation

2004 ◽  
Vol 91 (3) ◽  
pp. 393-401 ◽  
Author(s):  
Pekka Puska ◽  
Vesa Korpelainen ◽  
Lars H. Høie ◽  
Eva Skovlund ◽  
Knut T. Smerud
Keyword(s):  
Ldl Cholesterol ◽  
Intervention Group ◽  
Gastrointestinal Symptoms ◽  
Hdl Cholesterol ◽  
Dropout Rate ◽  
Soya Protein ◽  
Lipid Lowering ◽  
Control Group ◽  
Lowering Effect ◽  
Lipid Lowering Effect

The objective was to study whether a yoghurt containing isolated soya protein with standardised levels of isoflavones, cotyledon soya fibres and soya phospholipids is more effective in lowering total and LDL-cholesterol than a placebo. One hundred and forty-three subjects were randomised to the soya group (n69) or to the placebo (n74). The mean baseline levels were 7·6 and 5·1mmol/l for total and LDL-cholesterol, respectively. Fasting serum lipoproteins were assessed five times during the 8-week intervention period, and 4 weeks thereafter. The results were analysed by a mixed model for unbalanced repeated measurements. During the intervention, there were highly significant differences in lipid-lowering effect in favour of the active soya intervention group compared with the control group. The significant differences were for total cholesterol (estimated mean difference 0·40mmol/l;P<0·001), LDL-cholesterol (0·39mmol/l;P<0·001), non-HDL-cholesterol (0·40mmol/l;P<0·001) and for the total:HDL-cholesterol ratio (0·23;P=0·005). There was no difference in the effects on HDL-cholesterol, triacylglycerols or homocysteine. The lipid-lowering effect occurred within 1–2 weeks of intervention, and was not due to weight loss. The safety profile for active soya was similar to the placebo group, except for gastrointestinal symptoms, which caused a significantly higher dropout rate (fourteenv. three subjects) among the subjects taking active soya.

Secondary prevention care and effect: Total and low-density lipoprotein cholesterol levels and lipid-lowering drug use in women and men after incident myocardial infarction – The Tromsø Study 1994–2016

2018 ◽  
Vol 17 (6) ◽  
pp. 563-570 ◽  
Author(s):  
Laila A Hopstock ◽  
Anne Elise Eggen ◽  
Maja-Lisa Løchen ◽  
Ellisiv B Mathiesen ◽  
Inger Njølstad ◽  
...  
Keyword(s):  
Ldl Cholesterol ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Lipid Lowering ◽  
Low Density ◽  
Lipid Levels ◽  
Treatment Target ◽  
Cholesterol Levels ◽  
Lipid Lowering Drug ◽  
Lowering Drug

Background: Secondary prevention guidelines after myocardial infarction (MI) are gender neutral, but underutilisation of treatment in women has been reported. Design: We investigated the change in total and low-density lipoprotein (LDL) cholesterol levels and lipid-lowering drug (LLD) use after first-ever MI in a population-based study. Methods: We followed 10,005 participants (54% women) attending the Tromsø Study 1994–1995 and 8483 participants (55% women) attending the Tromsø Study 2007–2008 for first-ever MI up to their participation in 2007–2008 and 2015–2016, respectively. We used linear and logistic regression models to investigate sex differences in change in lipid levels. Results: A total of 395 (MI cohort I) and 132 participants (MI cohort II) had a first-ever MI during 1994–2008 and 2007–2013, respectively. Mean change in total cholesterol was −2.34 mmol/L (SD 1.15) in MI cohort I, and in LDL cholesterol was −1.63 mmol/L (SD 1.12) in MI cohort II. Men had a larger decrease in lipid levels compared to women: the linear regression coefficient for change was −0.33 (95% confidence interval [CI] −0.51 to −0.14) for total cholesterol and −0.21 (95% CI −0.37 to −0.04) for LDL cholesterol, adjusted for baseline lipid value, age and cohort. Men had 73% higher odds (95% CI 1.15−2.61) of treatment target achievement compared to women, adjusted for baseline lipid value, age and cohort. LLD use was reported in 85% of women and 92% of men in MI cohort I, and 80% in women and 89% in men in MI cohort II. Conclusions: Compared to men, women had significantly less decrease in lipid levels after MI, and a smaller proportion of women achieved the treatment target.

scholarly journals Lactobacillus Rhamnosus Yoba Modulates Serum Cholesterol in Normo-Lipidemic Wistar Rats Fed a High Fat Diet (P20-013-19)

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Adaku Iwueke ◽  
Conrad Miruka ◽  
John Ejekwumadu ◽  
Ronald Kiiza ◽  
Pius Theophilus
Keyword(s):  
Body Weight ◽  
High Fat Diet ◽  
Wistar Rats ◽  
Ldl Cholesterol ◽  
Lactobacillus Rhamnosus ◽  
Hdl Cholesterol ◽  
Male Rats ◽  
Fermented Foods ◽  
Distilled Water ◽  
High Fat

Abstract Objectives The study was aimed at assessing the effects of Lactobacillus rhamnosus yoba on the serum lipid profile and body weight of male Wistar rats fed a high fat diet. Methods 20 seven week old male rats weighing between 120 g and 180 g were used for the study and divided into 4 groups of 5 rats each. The control group was fed normal mice pellets and distilled water, while the other groups were fed mice pellets supplemented with 3% cholesterol and 2% saturated fat in addition to any of distilled water, Lactobacillus rhamnosus yoba or Norvastatin respectively. The body weight was measured at the start of the study and after 2 weeks while serum parameters were measured after 8 weeks. Data was analyzed using SPSS Version 20. ANOVA and Tukey's tests determined significant differences in means at 95% confidence interval. Results Lactobacillus rhamnosus yoba significantly (P < 0.005) modulated weight gain, serum total cholesterol and triglycerides when compared to the control. Similarly, LDL-cholesterol was significantly modulated (P < 0.005) while HDL-cholesterol was significantly enhanced (P < 0.005) when compared to the control. Conclusions The ability of Lactobacillus rhamnosus yoba to elevate HDL cholesterol and modulate LDL-cholesterol without the side effects of statins makes it a potential functional food. In line with the findings, the present study justifies the use of Lactobacillus rhamnosus yoba as a probiotic in fermented foods. Funding Sources NA.

FC23-02 - Gender and genotype modulation of the association between lipid levels and depressive symptomatology in community-dwelling elderly

2011 ◽  
Vol 26 (S2) ◽  
pp. 1940-1940
Author(s):  
M.-L. Ancelin ◽  
I. Carrière ◽  
J.-P. Boulenger ◽  
A. Malafosse ◽  
R. Stewart ◽  
...  
Keyword(s):  
Apolipoprotein E ◽  
Ldl Cholesterol ◽  
Hdl Cholesterol ◽  
Community Dwelling ◽  
Lipid Lowering ◽  
Lipid Levels ◽  
Genetic Vulnerability ◽  
Cholesterol Levels ◽  
Low Hdl ◽  
Gender Specific

BackgroundLipids appear to mediate depressive vulnerability in the elderly, however, sex differences and genetic vulnerability have not been taken into account in previous prospective studies.MethodsDepression was assessed in a population of 1040 women and 752 men aged 65 years and over at baseline and after 7-year follow-up. Clinical level of depression (DEP) was defined as having either a score of 16 and above on the Centre for Epidemiology Studies Depression scale or a diagnosis of current major depression on the Mini International Neuropsychiatric Interview. Lipid levels, apolipoprotein E and serotonin transporter linked promoter region (5-HTTLPR) genotypes were evaluated at baseline.ResultsMultivariate analyses adjusted by socio-demographic and behavioral variables, measures of physical health including ischemic pathologies, and genetic vulnerability indicated gender-specific associations between dyslipidemia and DEP, independent of the use of lipid lowering agents or apolipoprotein E status. Men with low LDL-cholesterol levels had twice the risk of prevalent and incident DEP whereas in women low HDL-cholesterol levels were found to be significantly associated with increased prevalent DEP (OR = 1.5) only. A significant interaction was observed between low LDL-cholesterol and 5-HTTLPR genotype, men with s/s or s/l genotype being at increased risk of DEP (OR = 6.0 and 2.7, respectively). No significant gene-environment interaction was observed for women.ConclusionsDEP is associated with higher atherogenic risk in women (low HDL-cholesterol), whereas the reverse is observed in men (low LDL-cholesterol). Late-life depression may have a complex gender-specific etiology involving genetic vulnerability in men.

scholarly journals Hypoglycaemic and Hypolipidemic Effects of Treculia africana Aqueous Leaves Extract in Alloxan Induced Diabetic Rats

2018 ◽  
pp. 1-9
Author(s):  
Idris A. Kankara ◽  
Gayus A. Paulina ◽  
M. Aliyu
Keyword(s):  
Body Weight ◽  
Blood Glucose ◽  
Total Cholesterol ◽  
Ldl Cholesterol ◽  
Fasting Blood Glucose ◽  
Hdl Cholesterol ◽  
Diabetic Control ◽  
Diabetic Rats ◽  
Albino Rats ◽  
Treculia Africana

This study investigated the hypoglycaemic and hypolipidaemic effects of Treculia africana plant used in Nigeria as medicinal plant. Diabetes mellitus was induced by a single dose intraperitoneal injection of alloxan 150 mg/kg body weight. Twenty five (25) male albino rats were divided into five groups, five (5) rats per group; normal control, diabetic control and diabetic groups treated with aqueous leaves extract of 200,400 and 800 mg/Kg body weight respectively for 21 days orally. The effects of the extract on some biochemical parameters were evaluated; fasting blood glucose level was assayed using glucose oxidase method, total cholesterol and HDL –cholesterol were assayed using enzymatic method while LDL- cholesterol was determined by Friedewald equation. The results showed that, extract significantly (p<0.05) decrease the elevated fasting blood glucose levels, total cholesterol, triglyceride and LDL- cholesterol when compared with the diabetic control rats. The extract also caused significant (p<0.05) increased in HDL –cholesterol and body weight when compared with diabetic control rats. Aqueous leave extract of Treculia africana possess hypoglycemic effect and the most effective dose was 800 mg/Kg body weight in amelioration of hyperglycaemia and most all toxicity effects of alloxan on lipid profile.

scholarly journals Current Practices and Attitudes Toward Cholesterol Management in Patients With Recent Acute Myocardial Infarction: A Survey of Community Physicians

Circulation ◽  
2001 ◽  
Vol 103 (suppl_1) ◽  
pp. 1358-1359
Author(s):  
Jorge L Yarzebski ◽  
Carmen Bujor ◽  
Robert J Goldberg ◽  
Frederick A Spencer ◽  
Darleen Lessard ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Drug Therapy ◽  
Ldl Cholesterol ◽  
Lipid Lowering ◽  
Dietary Therapy ◽  
High Cholesterol ◽  
Cholesterol Levels ◽  
Lipid Lowering Drug ◽  
Lowering Drug ◽  
Cholesterol Management

P41 Background: Recurrent coronary events and mortality are associated with elevated serum cholesterol levels in patients with acute myocardial infarction (AMI). It’s unclear what physicians’ current attitudes and practices are toward the management of high cholesterol levels in patients with recent AMI. We carried out a survey of practicing physicians to examine factors that influence physicians prescription of lipid-lowering and dietary therapy in patients with recent AMI and threshold levels of cholesterol for intervention. Methods: Mailed questionnaire survey of general internists, cardiologists, and family physicians practicing and/or having admitting privileges to all Worcester (MA) metropolitan hospitals. Results: Among the 257 responding physicians, lipid lowering therapy was more likely to be initiated in younger patients at lower total and LDL-cholesterol levels than in older patients. Younger physicians were more likely to initiate dietary and lipid lowering drug therapy at lower total and LDL-cholesterol levels. General practice physicians were more likely to initiate dietary therapy at lower total cholesterol levels, but more likely to initiate lipid lowering drug therapy at higher total and LDL-cholesterol levels, than internists and cardiologists. The most important factors reported by physicians which interfered with patient’s use of lipid lowering drug therapy were their concerns about medication costs, issues related to polypharmacy, and failure to recognize the importance of lipid lowering drugs. Several physician associated factors including provider responsibility and importance of other cardiac drugs were associated with the more widespread use of these medications. Conclusions: Results of this survey in a representative sample of community physicians suggest that older physicians are less likely to implement recommended treatment guidelines in patients with recent AMI and high cholesterol. Additional efforts are needed to modify potential barriers to the implementation of effective long-term cholesterol management in patients with recent AMI.

Sign in / Sign up

Export Citation Format

Share Document